StockData
YD Bio Ltd logo

YD Bio Ltd (YDES) shareholders

YDESNasdaqServices-Medical LaboratoriesFiscal year ends December 31Also trades as YDESW
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 30, 2026Score 5/30
$4.73−0.10 (-2.07%)

Close on Nov 17, 2026Market cap $334.83MP/E –Yield –

Ownership

Who owns YD Bio's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
3 buys · 0 sales
Net bought $128.53K

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Ethan Shen
Joint filing with YD Biopharma Holding Limited (61.15%)
54,345,01177.06%13G (passive) amendmentFeb 17, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Ethan Shen PhDCEO, Director54,379,189Sep 16, 2026
Bo-Xiang ZhangChief Medical Officer, Director31,141Mar 27, 2026
Man Edmund HenChief Financial Officer–Mar 26, 2026
Kochi ChangDirector10,965Oct 6, 2026
Shao-Ta LuDirector62,116Oct 6, 2026
Jerry Yin-Chia LeeDirector–Mar 30, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Shao-Ta Lu
Director
Sep 30, 2026Option exercise+3,135––10,965
Kochi Chang
Director
Sep 30, 2026Option exercise+3,135––10,965
Ethan Shen PhD
CEO, Director
Sep 14, 2026Buy+12,700$3.85$48.90K11,258,331
Ethan Shen PhD
CEO, Director
Sep 9, 2026Buy+3,100$3.93$12.18K11,245,631
Ethan Shen PhD
CEO, Director
Sep 4, 2026Buy+18,378$3.67$67.45K11,242,531
Shao-Ta Lu
Director
Jun 30, 2026Option exercise+5,749––7,830
Kochi Chang
Director
Jun 30, 2026Option exercise+5,749––7,830
Shao-Ta Lu
Director
Mar 31, 2026Option exercise+2,081––2,081
Kochi Chang
Director
Mar 31, 2026Option exercise+2,081––2,081

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.5
At 0M shares a day
Change since last report
-2.5%
From 0M shares
Short volume, 20 days
47.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of YD Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 122,170 shares on Sep 28, 2026 over the last 90 days.

See a number that looks wrong?